Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Malignant melanoma in the 21st century: the emerging molecular landscape.
Sekulic A, Haluska P Jr, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN; Melanoma Study Group of Mayo Clinic Cancer Center. Sekulic A, et al. Mayo Clin Proc. 2008 Jul;83(7):825-46. doi: 10.4065/83.7.825. Mayo Clin Proc. 2008. PMID: 18613999 Free PMC article. Review.
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Schmults CD, Blitzblau R, Aasi SZ, Alam M, Amini A, Bibee K, Bordeaux J, Chen PL, Contreras CM, DiMaio D, Donigan JM, Farma JM, Ghosh K, Harms K, Ho AL, Lukens JN, Mark L, Medina T, Nehal KS, Nghiem P, Olino K, Park S, Patel T, Puzanov I, Rich J, Sekulic A, Shaha AR, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu YG, Yu S, Yusuf M, McCullough B, Espinosa S. Schmults CD, et al. Among authors: sekulic a. J Natl Compr Canc Netw. 2023 Nov;21(11):1181-1203. doi: 10.6004/jnccn.2023.0056. J Natl Compr Canc Netw. 2023. PMID: 37935106
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024.
Schmults CD, Blitzblau R, Aasi SZ, Alam M, Amini A, Bibee K, Bolotin D, Bordeaux J, Chen PL, Contreras CM, DiMaio D, Donigan JM, Farma JM, Ghosh K, Harms K, Ho AL, Lukens JN, Manber S, Mark L, Medina T, Nehal KS, Nghiem P, Olino K, Park S, Patel T, Puzanov I, Rich J, Sekulic A, Shaha AR, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu YG, Yu S, Yusuf M, McCullough B, Espinosa S. Schmults CD, et al. Among authors: sekulic a. J Natl Compr Canc Netw. 2024 Jan;22(1D):e240002. doi: 10.6004/jnccn.2024.0002. J Natl Compr Canc Netw. 2024. PMID: 38244274
Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer.
Budhraja KK, McDonald BR, Stephens MD, Contente-Cuomo T, Markus H, Farooq M, Favaro PF, Connor S, Byron SA, Egan JB, Ernst B, McDaniel TK, Sekulic A, Tran NL, Prados MD, Borad MJ, Berens ME, Pockaj BA, LoRusso PM, Bryce A, Trent JM, Murtaza M. Budhraja KK, et al. Among authors: sekulic a. Sci Transl Med. 2023 Jan 11;15(678):eabm6863. doi: 10.1126/scitranslmed.abm6863. Epub 2023 Jan 11. Sci Transl Med. 2023. PMID: 36630480 Free PMC article.
Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica: A Prospective, Open-Label Study.
Hwang AS, Kechter JA, Li X, Hughes A, Severson KJ, Boudreaux B, Bhullar P, Nassir S, Yousif M, Zhang N, Butterfield RJ, Nelson S, Xing X, Tsoi LC, Zunich S, Sekulic A, Pittelkow M, Gudjonsson JE, Mangold A. Hwang AS, et al. Among authors: sekulic a. J Invest Dermatol. 2024 Feb 27:S0022-202X(24)00159-3. doi: 10.1016/j.jid.2023.11.027. Online ahead of print. J Invest Dermatol. 2024. PMID: 38417541
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.
Lewis KD, Peris K, Sekulic A, Stratigos AJ, Dunn L, Eroglu Z, Chang ALS, Migden MR, Yoo SY, Mohan K, Coates E, Okoye E, Bowler T, Baurain JF, Bechter O, Hauschild A, Butler MO, Hernandez-Aya L, Licitra L, Neves RI, Ruiz ES, Seebach F, Lowy I, Goncalves P, Fury MG. Lewis KD, et al. Among authors: sekulic a. Ann Oncol. 2024 Feb;35(2):221-228. doi: 10.1016/j.annonc.2023.10.123. Epub 2023 Dec 9. Ann Oncol. 2024. PMID: 38072158 Free article. Clinical Trial.
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.
Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Fernández Orland A, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Yoo SY, Okoye E, Bassukas I, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Inocencio TJ, Chen CI, LaFontaine PR, Seebach F, Lowy I, Fury MG. Stratigos AJ, et al. Among authors: sekulic a. J Am Acad Dermatol. 2024 Feb;90(2):414-418. doi: 10.1016/j.jaad.2023.08.111. Epub 2023 Oct 14. J Am Acad Dermatol. 2024. PMID: 37839734 Free article. Clinical Trial. No abstract available.
Guidelines of care for the management of basal cell carcinoma.
Work Group; Invited Reviewers; Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Work Group, et al. J Am Acad Dermatol. 2018 Mar;78(3):540-559. doi: 10.1016/j.jaad.2017.10.006. Epub 2018 Jan 10. J Am Acad Dermatol. 2018. PMID: 29331385
New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk.
Branković M, Dukić M, Gmizić T, Popadić V, Nikolić N, Sekulić A, Brajković M, Đokić J, Mahmutović E, Lasica R, Vojnović M, Milovanović T. Branković M, et al. Among authors: sekulic a. Diagnostics (Basel). 2024 Jan 22;14(2):229. doi: 10.3390/diagnostics14020229. Diagnostics (Basel). 2024. PMID: 38275476 Free PMC article. Review.
122 results